# IQVIA Holdings Inc. – Consensus ‘buy’ rating and 5.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/iqvia-holdings-inc.consensus-buy-rating-and-5.2-upside-potential/4121135130
- Published: 2023-12-05T13:08:22+00:00
- Author: Charlotte Edwards

**IQVIA Holdings Inc.** which can be found using ticker (IQV) have now 19 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between $265.00 and 
$190.00 and has a mean target at $228.21. Given that the stocks previous close was
at $216.91 and the analysts are correct then we can expect a percentage increase
in value of 5.2%. Also worth taking note is the 50 day moving average now sits at
$197.85 while the 200 day moving average is $205.50. The company has a market capitalization
of 39.47B. The stock price for the company is currently is currently $216.27 USD

 The potential market cap would be $41,525,442,562 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of 36.23, revenue per share of $80.44 and a 4.9% return on assets.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions
and clinical research services to the life sciences industry. The Company operates
through three segments: Technology & Analytics Solutions, Research & Development
Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions
segment provides critical information, technology solutions and real-world insights
and services to the Company’s life science clients. The Research & Development Solutions
segment primarily serves biopharmaceutical customers, providing outsourced clinical
research and clinical trial related services. The Contract Sales & Medical Solutions
segment provides health care provider, including contract sales and patient engagement
services to both biopharmaceutical clients and the broader healthcare market. The
Company protects individual patient privacy. The Company conducts business in more
than 100 countries.

Share on: